妇科再造丸在再次体外受精-胚胎移植助孕肾虚肝郁血瘀症患者中的应用  

Application of Fuke Zaizao pills in treatment of recurrent IVF-ET-assisted pregnancy in patients with kidney deficiency,liver depression and blood stasis syndrome

作　　者：王静欣 水丽君 祝心怡 周桂香 栾红兵 郑圣霞 WANG Jing-xin;SHUI Li-jun;ZHU Xin-yi;ZHOU Gui-xiang;LUAN Hong-bing;ZHENG Sheng-xia(Wannan Medical College,Wuhu 241000,China;The First Affiliated Hospital of University of Science and Technology of China,Hefei 230001,China)

机构地区：[1]皖南医学院,芜湖241000 [2]中国科学技术大学附属第一医院,合肥230001

出　　处：《中国新药杂志》2024年第18期1911-1917,共7页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助项目(81971339)。

摘　　要：目的:探讨妇科再造丸预处理对体外受精-胚胎移植(in vitro fertilization and embryo transfer,IVF-ET)的肾虚肝郁血瘀症患者再次助孕的自身对照临床疗效,为妇科再造丸辅助IVF-ET治疗提供数据支持。方法:选择2017年1月—2019年12月在中国科学技术大学附属第一医院(安徽省立医院)生殖与遗传分院接受IVF-ET治疗的肾虚肝郁血瘀症37例患者为研究对象,经妇科再造丸预治疗后再次助孕,分为对照组(治疗前)和用药组(治疗后),比较两组的基础促卵泡刺激素(follicle stimulating hormone,FSH)、黄体生成素(luteinizing hormone,LH)、雌激素(estrogen,E2)、抗缪勒管激素(anti-mullerian hormone,AMH)、窦卵泡数(antral follicle count,AFC)及IVF结局。结果:因为采用自身对照,两组患者年龄、不孕年限等自身因素相关数据匹配。基础FSH,LH,E2,AMH,AFC在用药前后差异无统计学意义;而促排天数、人绒毛膜促性腺激素(human chorionic gonadotropin,HCG)日子宫内膜厚度、受精卵数、获胚数、可用胚胎数、优质胚胎数、囊胚形成数、获卵率、受精率、成熟卵率、可用胚胎率、优质胚胎率、囊胚形成率、用药组较对照组有明显改善(P<0.05);卵巢储备功能、促排卵药物用量、>14 mm卵泡数、获卵数、成熟卵数、用药组与对照组比较没有明显差异;统计用药组妊娠结局,生化妊娠率3.13%、临床妊娠率59.38%、累计活产率53.13%、流产率10.53%。结论:在IVF-ET助孕过程中对于肾虚肝郁血瘀型患者运用妇科再造丸预处理能提高可用胚胎数量、改善胚胎质量,获得更好的妊娠结局,值得临床推广应用。Objective:To investigate the clinical effect of pretreatment with Fuke Zaizao pills(FKW)in patients undergoing in vitro fertilization and embryo transfer(IVF-ET)again,who have kidney deficiency,liver depression,and blood stasis,to provide data support for the treatment using FKW to assist IVF-ET.Methods:A total of 37 patients with kidney deficiency,liver depression,and blood stasis who underwent IVF-ET at the Fertility and Genetics Branch of the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)from January 2017 to December 2019 were selected as study subjects.These patients received pre-treatment with FKW before attempting pregnancy again.Basal follicle-stimulating hormone(FSH),luteinizing hormone(LH),estrogen(E2),anti-Mullerian hormone(AMH),sinus follicle number(AFC),and IVF outcomes were compared between the two groups.Results:Through self-control measures,both groups had matched patient age,infertility years,and other relevant data.There was no statistical difference observed in FSH,LH,E2,AMH or AFC before and after treatment.However,compared to the control group,significant improvements were seen in various parameters including the number of Gn days,endometrial thickness in HCG days,numbers of obtained embryos,obtained fertilized eggs,available embryos,and high-quality embryos,blastocyst formation rate,eggs acquisition rate,fertilization rate,mature eggs rate,the availability rate of embryos,the quality rate of high-quality embryos,and the blastocy stformation rate.The number of follicles(>14 mm),obtained oocytes,and mature eggs were not significantly different from those in the control group.Statistical pregnancy outcome was achieved in the medication group:the biochemical pregnancy rate was 3.13%,the clinical pregnancy rate was 59.38%,the cumulative live birth rate was 53.13%,and the abortion rate was 10.53%.Conclusion:In the process of IVFET-assisted pregnancy for patients with kidney deficiency,liver depression,and blood stasis,pretreatment with FKW can

关 键 词：体外受精-胚胎移植 妇科再造丸 肾虚肝郁血瘀症 胚胎质量 

分 类 号：R96[医药卫生—药理学]